SACCSCANProject ID: 729909
H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
H2020-EU.3.1.4. - Active ageing and self-management of health
H2020-EU.3.1.6. - Health care provision and integrated care
SACCSCAN - personalising clinical management of major psychiatric disorders
Total cost:EUR 71 429
EU contribution:EUR 50 000
Coordinated in:United Kingdom
Topic(s):SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well
Call for proposal:H2020-SMEINST-1-2016-2017See other projects for this call
Funding scheme:SME-1 - SME instrument phase 1
1 in 5 of us experience mental health problems during our lifetime but more than 50% of patients don’t receive adequate care. Currently, when patients’ symptoms and behaviour don’t meet the criteria set out in the diagnostic manual, it may take up to 10 years to diagnose the illness. Delays in receiving a diagnosis can significantly impede delivery of the most effective treatment plan, exposing the patient to risk of further deterioration in well-being, reduction in quality of life leading to job loss, family breakdown, and self-harming. Mental ill health is now recognised as the largest cause of short and long term disability worldwide costing the global economy US$2.5T with a projected increase to over US$6T by 2030.
SaccScan is a novel point-of-care (PoC) software diagnostic system which has been demonstrated to detect schizophrenia with better than 95% accuracy and has been extended with the same precision to bipolar disorder and major depression illnesses. The software diagnostic tool successfully utilises eye-movement abnormalities as clinical diagnostic biomarkers for serious mental illnesses. The test can be performed within 30 minutes and results produced over the internet at near real-time speed. Early economic modelling showed that introducing SaccScan into health care services could produce savings of €33 474 per patient in the case of suspected schizophrenia. The global market for this test is in excess of €5 billion with early-adopter customer segments making up over 10% of the total market - creating a potential initial market share of €100 million per annum.
The purpose of this Phase 1 application is to demonstrate proof of business and develop the necessary partnerships for bringing a minimum viable version to market. Further support from H2020 SME Instrument, will help complete clinical validation and fully commercialise SaccScan in Phase 2 and Phase 3, while addressing the EU challenge of reducing healthcare costs through personalising medicine.
EU contribution: EUR 50 000
2 LISTER SQUARE
EH3 9GL EDINBURGH